Related Content
Search Google Scholar for:
More Information
Related Jobs from ScienceCareers
|
Science 26 September 1997: Vol. 277.
no. 5334, pp. 1948 - 1949 DOI:
10.1126/science.277.5334.1948 |
|
Perspectives
DNA METHYLATION: Tying It All
Together: Epigenetics, Genetics, Cell Cycle, and CancerStephen
B. Baylin
In eukaryotic cells, the methylation state of the base
cytosine can be inherited without altering genetic material per se (1).
This unusual--or "epigenetic"--form of inheritance generates patterns of
DNA methylation that modulate overall genomic patterns of chromatin
organization and gene expression. On page 1996
of this issue (2),
Chuang et al. provide a potentially important entrée for
understanding how, in humans, these patterns of DNA methylation are
established and maintained. Further, their results show how epigenetic and
genetic aspects of cancer might be married through events that control the
cell cycle.
In higher order eukaryotes, DNA methylation and DNA-protein
interactions together organize the genome into transcriptionally active
and inactive zones (3).
This organizational role is facilitated by an asymmetric pattern of DNA
methylation. DNA methylation is absent in Drosophila,
Caenorhabditis elegans, and yeast, but appeared as the vertebrate
genome became more complex. Concurrently, during evolution, the CpG
dinucleotide, the principal site of DNA methylation, has been selectively
depleted through conversion of methylated cytosines to thymidines via a
deamination process (3).
The human genome has only 10% of the expected frequency of CpG's, and 70
to 80% of these are methylated (3).
However, small regions of DNA remain (1 to 2%), termed "CpG islands," that
are not CpG-depleted. These are rigorously protected from methylation and
are associated with the transcription start sites in almost half, or some
40,000, human genes (4).
What is the purpose of this division of the genome? DNA methylation
patterns closely correlate with patterns of gene expression. Heavily
methylated DNA is generally associated with chromatin organization that is
inhibitory to transcription (3).
In humans, such repressed DNA often contains highly repeated sequences;
methylation may help guard against transcriptional expression of these
"parasitic" regions, which were introduced into the genome over evolution
by transposable elements and DNA viruses (5).
In contrast, the unmethylated CpG islands of most genes are associated
with chromatin typical of highly transcribed DNA (3).
But selected CpG islands are densely methylated. These regions have
chromatin conformation typical of nontranscribed DNA and represent
silenced alleles for mono-allelically expressed or "imprinted genes" (6)
and for many genes on the transcriptionally inactivated X chromosome of
the female (3).
These normally silenced alleles can be expressed, and their CpG islands
unmethylated, in mouse embryos with homozygous deletions of the
DNA-methyltransferase (DNA-MCMT) gene, which encodes the major
DNA-methylating enzyme (7).
The methylation patterns generated by this enzyme are essential, because
these mice die in early embryogenesis (8).
Cancer cells show altered patterns of DNA methylation (9).
Overall DNA methylation is often decreased (10).
This change may contribute to genomic instability (11).
In these same tumors, the normally unmethylated CpG islands in the
promoter region of critical genes can become densely methylated, and the
associated transcriptional silencing is an epigenetic alternative to
coding region mutations for causing loss of tumor suppressor gene function
(9).
Indeed, almost half of the suppressor genes known to underlie genetic
forms of neoplasia--including VHL and p16 (12)--when
mutated in the germ line exhibit CpG island hypermethylation in
noninherited cancers.
What do the new findings of Chuang et al. reflect about DNA
methylation? One mystery has been how DNA-MCMT activity is coordinated
with DNA replication to maintain both normal and abnormal DNA methylation
patterns. This enzyme, conserved from sea urchin to human (13),
preferentially methylates DNA that is already methylated on one strand.
Thus, during DNA replication, DNA-MCMT recognizes methylated CpG sites on
the parent strand and methylates correlating cytosines on the daughter
strand (13).
Chuang et al. now suggest that binding of the enzyme to a
protein, proliferating cell nuclear antigen (PCNA), coordinates DNA-MCMT
activity and DNA replication and that this step is negatively regulated by
the protein p21.
PCNA facilitates DNA replication by loading delta and epsilon DNA
polymerases onto DNA in cycling cells and during DNA repair (14).
In intact cells, DNA-MCMT and PCNA were found by Chuang et al. to
colocalize to DNA replication foci in early S phase, the cycle period for
DNA synthesis. Such complexes are absent in G1, which precedes
the onset of DNA synthesis. p21 could regulate these interactions in
several ways. First, p21 binds PCNA (15)
through a region found by Chuang et al. to be similar to, and to
compete with, the site in DNA-MCMT that mediates PCNA binding. Second,
when complexed with PCNA, p21 inhibits DNA synthesis (16).
Finally, p21 also forms complexes with the cyclins, proteins that activate
a series of cyclin-dependent kinases (CDKs) that allow cells to cycle and
synthesize DNA (17).
p21, by inhibiting this activity, especially at the G1/S
border, participates in the cell's decision whether to synthesize DNA (17).
How might these dynamics mediate normal and abnormal DNA methylation?
Perhaps, in normal cells, when PCNA targets DNA-MCMT to early DNA
replication foci, strategic placement of, or amounts of, p21 negatively
modulate the complex such that early replicating DNA regions like CpG
islands (18)
are protected from methylation (see figure, top panel). Similarly, a
diminished effect of p21 later in S phase, at the peak of PCNA
localization to DNA (19),
might positively regulate DNA-MCMT at normal sites of methylation (see
figure, top panel).
Proposed control of DNA
methylation. In normal cells, the p21 protein negatively
regulates targeting of DNA-MCMT to PCNA, primarily in early S phase, and
protects CpG islands from methylation. Diminished effects of p21 in late S
phase may target DNA-MCMT to methylated DNA. Other local regulators of
methylation help block methylation of CpG islands in early S (symbol with
?) and facilitate interaction of DNA-MCMT with heavily methylated
late-replicating DNA (symbol with ?). In cancer cells, loss of p21
function allows increased DNA-MCMT more access, via PCNA, to DNA
replication foci, possibly facilitating aberrant methylation of CpG
islands. Decreased relative targeting to late S phase foci results in lost
sites of normal methylation. Also, decreased activity of early S phase
negative modulators of methylation and of late S phase positive regulators
(symbol with ?) may facilitate the aberrant methylation patterns.
Further, as stressed by Chuang et al., loss of p21 function is
a very common event in human cancers. Normally, the transcription of p21
is directly stimulated by p53, in a pathway for sensing DNA damage and
signaling cells to die or cease DNA synthesis until DNA damage is repaired
(20).
p53 mutations are common in human cancer (21)
leading to loss of p21 function. Other pathways signal increases in p21
and may also be lost in tumors (17).
Chuang et al. then propose that, when p21 losses are juxtaposed
with increased DNA-MCMT activity, as in SV40 transformation, this
imbalance contributes to altered DNA methylation.
The significance of tumor-associated increases in DNA-MCMT activity (22)
has been debated. Normal cells increase DNA-MCMT activity during DNA
synthesis and the increase in tumors could simply be a nonfunctional
consequence of increased cell cycling (23).
However, DNA-MCMT increases may actually be pivotal for driving
tumorigenesis. Increases in DNA-MCMT activity and overall DNA methylation
occur in specific cells after carcinogen exposure (24).
Also, insertion of the gene for DNA-MCMT can cause cellular transformation
(25)
and hypermethylation of selected CpG islands (26).
Genetically engineered lowering of DNA-MCMT activity can slow tumor
progression (27).
The loss of p21 might facilitate increased DNA-MCMT effects in tumors by
simultaneously allowing unchecked cell cycling, increased DNA synthesis,
and shifting of increased DNA-MCMT-PCNA complexes from late to early DNA
replication (see figure, lower panel). Both abnormal gains and losses of
DNA methylation sites might ensue. Further, Chuang et al. suggest
that in tumors p21 loss from PCNA complexes could cause abnormal gains of
methylation during repair of DNA damage. This is intriguing because both
increased methylation of inserted gene sequences (11)
and of endogenous gene CpG islands (28)
have been found in a type of colon cancer associated with mismatch repair
deficiency.
These new findings thus potentially bring together the fields of DNA
methylation, cell cycle regulation, control of chromatin organization, and
cancer genetics. However, the future challenge is to integrate them with
other events that could modulate DNA methylation. First, p21 is only one
of a number of related proteins that might modulate PCNA-DNA-MCMT (29).
Second, other proteins likely influence DNA methylation such as
transcription factors that may block access of DNA-MCMT to CpG islands (30).
Some transcriptional coactivators alter chromatin organization by
controlling the acetylation of histones and other proteins (31).
Histone variant H1 inhibits the activity of DNA-MCMT for CpG-rich
sequences (32).
Further, proteins that bind preferentially to methylated cytosines could
help guide DNA-MCMT to areas of normal methylation. One such protein MeCP1
(methyl-CPG binding protein) shares a domain with the enzyme itself and
with a mammalian homolog to a chromatin modeling protein in
Drosophila (33).
Finally, the initial unmethylated status of CpG islands lessens their
affinity for DNA-MCMT, given its preference for hemimethylated DNA, and
CpG-rich areas may be poor intrinsic substrates for DNA-MCMT (34).
Also, specific demethylation events could help protect CpG islands (35).
Exploring all of these interacting events, including the role of proposed
additional DNA-MCMTs (36),
will dominate DNA methylation research over the next years. The knowledge
gained should prove invaluable for understanding how this DNA modification
is essential for normal cell function and, when disrupted, can contribute
to cancer and other disease states.
References and Notes
- A. Bird, Cell
70, 5 (1992) [Medline].
- L. S. H. Chuang et al.,
Science 277, 1996
(1997).
- F. Antequera and A. Bird, in DNA
Methylation: Molecular Biology and Biological Significance, J. P.
Jost and H. P. Saluz, Eds. (Birkhauser Verlag, Basel, 1993), p. 169.
- , Proc. Natl. Acad. Sci. U.S.A. 90,
11995 (1993) [Medline].
- M. S. Turker and T. H. Bestor,
Mutat. Res. 386, 119 (1997) [Medline];
T. H. Bestor and B. Tycko, Nat. Genet. 12, 363
(1996) [Medline].
- D. P. Barlow, Science
270, 1610 (1995) [Medline].
- E. Li, C. Beard, R. Jaenisch,
Nature 366, 362 (1993) [Medline].
- E. Li, T. H. Bestor, R. Jaenisch,
Cell 69, 915 (1992) [Medline].
- P. W. Laird and R. Jaenisch, Hum.
Mol. Genet. 3, special issue no. 1487 (1994) [Medline];
P. A. Jones, Cancer Res. 56, 2463 (1996) [Medline];
S. B. Baylin, J. G. Herman, J. R. Graff, P. M. Vertino, J. Issa,
Adv. Cancer Res., in press.
- M. A. Gama-Sosa, et al., Nucleic
Acids Res. 11, 6883 (1983) [Medline];
S. E. Goelz, B. Vogelstein, S. R. Hamilton, A. P. Feinberg,
Science 228, 187 (1985) [Medline];
A. P. Feinberg, C. W. Gehrke, K. C. Kuo, M. Ehrlich, Cancer
Res. 48, 1159 (1988) [Medline].
- C. Lengauer, K. W. Kinzler, B.
Vogelstein, Proc. Natl. Acad. Sci. U.S.A. 94,
2545 (1997) [Medline].
- J. G. Herman et al., ibid.
91, 9700 (1994) [Medline];
A. Merlo et al., Nat. Med. 1, 686 (1995) [Medline].
- T. Bestor, A. Laudano, R. Mattaliano,
V. Ingram, J. Mol. Biol. 203, 971 (1988) [Medline];
J. A. Yoder, R. C. Yen, P. M. Vertino, T. H. Bestor, S. B. Baylin,
J. Biol. Chem. 271, 31092 (1996) [Medline];
K. L. Tucker, D. Talbot, M. A. Lee, H. Leonhardt, R. Jaenisch, Proc.
Natl. Acad. Sci. U.S.A. 93, 12920 (1996) [Medline].
- G. Prelich and B. Stillman,
Cell 53, 117 (1988) [Medline];
M. K. K. Shivji, M. K. Kenny, R. D. Wood, ibid.
69, 367 (1992) [Medline];
B. Stillman, ibid. 78, 725 (1994) [Medline];
A. Umar et al., ibid. 87, 65 (1996) [Medline].
- J. Chen, P. K. Jackson, M. W.
Kirschner, A. Dutta, Nature 374, 386 (1995) [Medline];
J. M. Gulbis, Z. Kelman, J. Hurwitz, M. O'Donnell, J. Kuriyan,
Cell 87, 297 (1996) [Medline].
- S. Waga, G. J. Hannon, D. Beach, B.
Stillman, Nature 369, 574 (1994) [Medline];
H. Flores-Rozas et al., Proc. Natl. Acad. Sci. U.S.A.
91, 8655 (1994) [Medline].
- S. J. Elledge, Science
274, 1664
(1996); C. J. Sherr, ibid., p. 1672.
- S. Selig, K. Okumura, D. C. Ward, H.
Cedar, EMBO J. 11, 1217 (1992) [Medline].
- G. F. Morris and M. B. Mathews,
J. Biol. Chem. 264, 13856 (1989) [Medline].
- A. J. Levine, Cell
88, 323 (1997) [Medline];
I. J. Ko and C. Prives, Genes Dev. 10, 1054
(1996) [Medline];
W. S. El-Deiry et al., Cell 75, 817
(1993) [Medline].
- B. Vogelstein and K. W. Kinzler,
Cell 70, 523 (1992) [Medline];
M. Hollstein, Science 253, 49 (1991) [Medline].
- J. P. Issa et al., J. Natl.
Cancer Inst. 85, 1235 (1993) [Medline];
T. L. Kautiainen and P. A. Jones, J. Biol. Chem.
261, 1594 (1986) [Medline].
- P. J. Lee et al., Proc. Natl.
Acad. Sci. U.S.A. 93, 10366 (1996) [Medline].
- S. A. Belinsky, K. J. Nikula, S. B.
Baylin, J.-P. Issa, ibid., p. 4045 [Medline].
- J. Wu et al., ibid.
90, 8891 (1993) [Medline].
- P. M. Vertino, R. C. Yen, J. Gao, S.
B. Baylin, Mol. Cell. Biol. 16, 4555 (1996) [Medline];
J. R. Graff, J. G. Herman, S. Myohanen, S. B. Baylin, P. M. Vertino,
J. Biol. Chem. 272, 22322 (1997) [Medline].
- P. W. Laird et al., Cell
81, 197 (1995) [Medline].
- N. Ahuja et al., Cancer Res.
57, 3370 (1997) [Medline].
- J. LaBaer et al., Genes Dev.
11, 847 (1997) [Medline];
C. J. Sherr and J. M. Roberts, ibid. 9, 1149
(1995) [Medline].
- M. Brandeis et al., Nature
371, 435 (1994) [Medline];
D. Macleod, J. Charlton, J. Mullins, A. P. Bird, Genes Dev.
8, 2282 (1994) [Medline];
P. Mummaneni, K. A. Walker, P. L. Bishop, M. S. Turker, J. Biol.
Chem. 270, 788 (1995) [Medline].
- P. A. Wade, D. Pruss, A. P. Wolffe,
Trends Biochem. Sci. 22, 128 (1997) [Medline];
M. J. Pazin and J. T. Kadonaga, Cell 89, 325
(1997) [Medline].
- R. Santoro et al., J.
Biochem. 305, 739 (1995).
- P. M. Waring and M. L. Cleary,
Curr. Top Microbiol. Immunol. 220, 1 (1997);
S. H. Cross, R. R. Meehan, X. Nan, A. Bird, Nat. Genet.
16, 256 (1997) [Medline].
- T. H. Bestor, G. Gundersen, A. B.
Kolsto, H. Prydz, Genet. Anal. Tech. Appl. 9,
48 (1992) [Medline].
- M. Szyf, J. Theberge, V. Bozovic,
J. Biol. Chem. 270, 12690 (1995) [Medline];
A. Weiss, I. Keshet, A. Razin, H. Cedar, Cell
86, 709 (1996) [Medline].
- H. Lei et al., Development
122, 3195 (1996) [Medline].
- I thank the members of my research
program for useful discussions and especially J. Graff, M. Rountree, and
J.-P. Issa.
The author is at the Johns Hopkins Comprehensive Cancer Center and the
Department of Medicine, Baltimore, MD 21231, USA. E-mail: sbaylin{at}welchlink.welch.jhu.edu
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- A perspective view of sodium iodide symporter research and its
clinical implications..
- G. Riesco-Eizaguirre and P. Santisteban (2006)
Eur. J.
Endocrinol. 155, 495-512 | Abstract
» | Full Text
» | PDF »
- A cascade of modules of a network defines cancer progression..
- S. Thiagalingam (2006)
Cancer Res. 66, 7379-7385
| Abstract
» | Full
Text » | PDF
»
- DNA methylation of multiple tumor-related genes in association with
overexpression of DNA methyltransferase 1 (DNMT1) during multistage
carcinogenesis of the pancreas.
- D.-F. Peng, Y. Kanai, M. Sawada, S. Ushijima, N. Hiraoka, S.
Kitazawa, and S. Hirohashi (2006)
Carcinogenesis 27,
1160-1168 | Abstract
» | Full
Text » | PDF »
- Histone Deacetylase Inhibitor-Mediated Radiosensitization of Human
Cancer Cells: Class Differences and the Potential Influence of p53.
- I. A. Kim, J. H. Shin, I. H. Kim, J. H. Kim, J. S. Kim, H. G. Wu, E.
K. Chie, S. W. Ha, C. I. Park, and G. D. Kao (2006)
Clin. Cancer Res.
12, 940-949 | Abstract
» | Full
Text » | PDF
»
- Differential DNA Hypermethylation of Critical Genes Mediates the
Stage-Specific Tobacco Smoke-Induced Neoplastic Progression of Lung
Cancer.
- A. L. Russo, A. Thiagalingam, H. Pan, J. Califano, K.-h. Cheng, J.
F. Ponte, D. Chinnappan, P. Nemani, D. Sidransky, and S. Thiagalingam
(2005)
Clin. Cancer Res. 11, 2466-2470
| Abstract
» | Full
Text » | PDF
»
- DNA Methylation and Cancer.
- P. M. Das and R. Singal (2004)
J. Clin. Oncol.
22, 4632-4642 | Abstract »
| Full Text »
| PDF »
- Elucidation of Epigenetic Inactivation of SMAD8 in Cancer Using
Targeted Expressed Gene Display.
- K.-h. Cheng, J. F. Ponte, and S. Thiagalingam (2004)
Cancer Res.
64, 1639-1646 | Abstract
» | Full
Text » | PDF »
- Increased DNA Methyltransferase 1 (DNMT1) Protein Expression
Correlates Significantly with Poorer Tumor Differentiation and Frequent
DNA Hypermethylation of Multiple CpG Islands in Gastric Cancers.
- T. Etoh, Y. Kanai, S. Ushijima, T. Nakagawa, Y. Nakanishi, M.
Sasako, S. Kitano, and S. Hirohashi (2004)
Am. J. Pathol.
164, 689-699 | Abstract
» | Full Text
» | PDF »
- Interleukin 12-based Immunotherapy Improves the Antitumor
Effectiveness of a Low-Dose 5-Aza-2'-Deoxycitidine Treatment in L1210
Leukemia and B16F10 Melanoma Models in Mice.
- K. Kozar, R. Kaminski, T. Switaj, T. Oldak, E. Machaj, P. J.
Wysocki, A. Mackiewicz, W. Lasek, M. Jakobisiak, and J. Golab
(2003)
Clin. Cancer Res. 9, 3124-3133
| Abstract
» | Full
Text » | PDF
»
- The Development of CpG Island Methylation Biomarkers Using
Restriction Landmark Genomic Scanning.
- D. J. SMIRAGLIA and C. PLASS (2003)
Ann. N.Y. Acad. Sci.
983, 110-119 | Abstract
» | Full Text
» | PDF »
- Overexpression of a splice variant of DNA methyltransferase 3b,
DNMT3b4, associated with DNA hypomethylation on pericentromeric
satellite regions during human hepatocarcinogenesis.
- Y. Saito, Y. Kanai, M. Sakamoto, H. Saito, H. Ishii, and S.
Hirohashi (2002)
PNAS 99, 10060-10065
| Abstract
» | Full Text »
| PDF »
- Patchy Field Defects of Apoptosis Resistance and Dedifferentiation
in Flat Mucosa of Colon Resections From Colon Cancer Patients.
- H. Bernstein, H. Holubec, J. A. Warneke, H. Garewal, D. L. Earnest,
C. M. Payne, D. J. Roe, H. Cui, E. L. Jacobson, and C. Bernstein
(2002)
Ann. Surg. Oncol. 9, 505-517 | Abstract
» | Full
Text » | PDF
»
- Global gene expression profiling of multiple myeloma, monoclonal
gammopathy of undetermined significance, and normal bone marrow plasma
cells.
- F. Zhan, J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, E. Tian, R.
Sanderson, Y. Yang, C. Wilson, M. Zangari, E. Anaissie, C. Morris, F.
Muwalla, F. van Rhee, A. Fassas, J. Crowley, G. Tricot, B. Barlogie, and
J. Shaughnessy Jr (2002)
Blood 99, 1745-1757
| Abstract
» | Full Text
» | PDF »
- Infection of Lymphoid Cells by Integration-Defective Human
Immunodeficiency Virus Type 1 Increases De Novo Methylation.
- J.-Y. Fang, J. A. Mikovits, R. Bagni, C. L. Petrow-Sadowski, and F.
W. Ruscetti (2001)
J. Virol. 75, 9753-9761
| Abstract »
| Full Text »
| PDF »
- Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal
hematopoiesis and in acute and chronic myelogenous leukemia.
- S.-i. Mizuno, T. Chijiwa, T. Okamura, K. Akashi, Y. Fukumaki, Y.
Niho, and H. Sasaki (2001)
Blood 97, 1172-1179
| Abstract
» | Full Text
» | PDF »
- Transcriptional Repression by Drosophila Methyl-CpG-Binding
Proteins.
- K. Roder, M.-S. Hung, T.-L. Lee, T.-Y. Lin, H. Xiao, K.-I. Isobe,
J.-L. Juang, and C.-K. J. Shen (2000)
Mol. Cell. Biol.
20, 7401-7409 | Abstract »
| Full Text »
- Response to "Epigenetic Mechanisms of Carcinogenesis" by Kamendunlis
JE, Kamendulis LM and Xu Y.
- J I Goodman (2000)
Human and Experimental Toxicology
19, 563-565 | PDF »
- Loss of Imprinting and Genetic Alterations of the Cyclin-dependent
Kinase Inhibitor p57KIP2 Gene in Head and Neck Squamous Cell Carcinoma.
- S. Lai, H. Goepfert, A. M. Gillenwater, M. A. Luna, and A. K.
El-Naggar (2000)
Clin. Cancer Res. 6, 3172-3176
| Abstract
» | Full
Text »
- Loss of chromosome 14 increases the radiosensitivity of CGL1 human
hybrid cells but lowers their susceptibility to radiation-induced
neoplastic transformation.
- M. S. Mendonca, L. A. Desmond, T. M. Temples, D. L. Farrington, and
B. M. Mayhugh (2000)
Mutagenesis 15, 187-193
| Abstract
» | Full
Text » | PDF »
- Cloning of a Mammalian Transcriptional Activator That Binds
Unmethylated CpG Motifs and Shares a CXXC Domain with DNA
Methyltransferase, Human Trithorax, and Methyl-CpG Binding Domain
Protein 1.
- K. Shin Voo, D. L. Carlone, B. M. Jacobsen, A. Flodin, and D. G.
Skalnik (2000)
Mol. Cell. Biol. 20, 2108-2121
| Abstract »
| Full Text »
- Suppression of Metallothionein Gene Expression in a Rat Hepatoma
Because of Promoter-specific DNA Methylation.
- K. Ghoshal, S. Majumder, Z. Li, X. Dong, and S. T. Jacob
(2000)
J. Biol. Chem. 275, 539-547 | Abstract »
| Full Text »
| PDF »
- Previous loss of chromosome 11 containing a suppressor locus
increases radiosensitivity, neoplastic transformation frequency and
delayed death in HeLa fibroblast human hybrid cells.
- M. S. Mendonca, K. Howard, L. A. Desmond, and C. W. Derrow
(1999)
Mutagenesis 14, 483-490 | Abstract
» | Full
Text » | PDF »
- Two major forms of DNA (cytosine-5) methyltransferase in human
somatic tissues.
- D.-W. Hsu, M.-J. Lin, T.-L. Lee, S.-C. Wen, X. Chen, and C.-K. J.
Shen (1999)
PNAS 96, 9751-9756 | Abstract
» | Full Text »
| PDF »
- Abnormal Regulation of DNA Methyltransferase Expression during
Colorectal Carcinogenesis.
- A. M. De Marzo, V. L. Marchi, E. S. Yang, R. Veeraswamy, X. Lin, and
W. G. Nelson (1999)
Cancer Res. 59, 3855-3860
| Abstract
» | Full
Text » | PDF
»
- Restoration of Iodide Uptake in Dedifferentiated Thyroid Carcinoma:
Relationship to Human Na+/I- Symporter Gene Methylation Status.
- G. M. Venkataraman, M. Yatin, R. Marcinek, and K. B. Ain
(1999)
J. Clin. Endocrinol. Metab. 84, 2449-2457
| Abstract
» | Full Text
»
- DNA Methylation.
- R. Singal and G. D. Ginder (1999)
Blood 93,
4059-4070 | Full Text
» | PDF »
- DNA Methylation Regulates p27Kip1 Expression in Rodent Pituitary
Cell Lines.
- X. Qian, L. Jin, E. Kulig, and R. V. Lloyd (1998)
Am. J. Pathol.
153, 1475-1482 | Abstract
» | Full Text
» | PDF »
- Evidence for gene silencing by endogenous DNA methylation.
- R. Holliday and T. Ho (1998)
PNAS 95, 8727-8732
| Abstract
» | Full Text »
| PDF »
|
|